
Nilüfer Alpay-Kanıtez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7748444/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pregnancy in Takayasu's arteritis has a high risk of hypertensionâ€related fetomaternal complications: A retrospective study of a Turkish cohort. International Journal of Rheumatic Diseases, 2022, 25, 140-146.	1.9	2
2	Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?. Rheumatology International, 2022, 42, 1797-1806.	3.0	0
3	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	6.2	26
4	Comparison of relapse rates in Behçet's disease with venous involvement on different doses of azathioprine therapy, a retrospective observational study. International Journal of Rheumatic Diseases, 2021, 24, 562-566.	1.9	4
5	COVID-19 Among Patients With Inflammatory Rheumatic Diseases. Frontiers in Immunology, 2021, 12, 651715.	4.8	15
6	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. Rheumatology International, 2021, 41, 1915-1924.	3.0	1
7	Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results. American Journal of Ophthalmology, 2021, 228, 58-64.	3.3	10
8	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences, 2021, 51, 1615-1623.	0.9	6
9	Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab. Seminars in Arthritis and Rheumatism, 2021, 51, 1224-1229.	3.4	15
10	Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis. Medicine (United States), 2020, 99, e19696.	1.0	9
11	Low dose colchicine use in familial Mediterranean fever patients whose disease is under control. Ulusal Romatoloji Dergisi, 2020, 12, 30-34.	0.0	0
12	Reply to: Endovascular embolisation with Amplatzer vascular plug of ruptured pulmonary artery aneurism in Behçet's disease: a commentary. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 121.	0.8	0
13	FRI0395â€SWITCHING RATE OF ANTI-TNF AGENTS IN SPONDYLOARTHRITIS PATIENTS: TREASURE – REAL LIF DATA. , 2019, , .	E	0
14	THU0410â€UVEITIS RELATED FACTORS IN PATIENTS WITH SPONDYLOARTHRITIS. , 2019, , .		0
15	OP0168â€DERIVATION AND VALIDATION OF A NEW STILL ACTIVITY SCORE (SAS). , 2019, , .		0
16	FRI0299â€THE PREVALENCE OF NON-VASCULAR PULMONARY MANIFESTATIONS IN PATIENTS WITH TAKAYAS ARTERITIS: A RETROSPECTIVE MULTI-CENTERED COHORT STUDY. , 2019, , .	U'	0
17	AB0575â€THE EFFECT OF METABOLIC SYNDROME ON CARDIOVASCULAR DISEASE AND CUMULATIVE ORGAN DAMAGE IN TAKAYASU'S ARTERITIS. , 2019, , .		0
18	FRI0098â€SWITCHING RATE OF BIOLOGICAL DMARDS IN RHEUMATOID ARTHRITIS PATIENTS: TREASURE – I LIFE DATA. , 2019, , .	REAL	0

#	Article	IF	CITATIONS
19	AB0723â€SMOKING MAY BE RELATED TO SACROILIITIS IN ENTEROPATHIC ARTHRITIS PATIENTS: TREASURE REAL-LIFE PRELIMINARY DATA. , 2019, , .		0
20	THU0524â€ARE CHILDREN AND ADULTS HAVING DIFFERENT PHENOTYPE AND GENOTYPE OF FMF?. , 2019, , .		1
21	Polyarthritis and its differential diagnosis. European Journal of Rheumatology, 2019, 6, 167-173.	0.6	8
22	Demographic, clinical, and laboratory features of Turkish patients with gouty arthritis: A prospective cohort study. European Journal of Rheumatology, 2019, 6, 1-6.	0.6	0
23	Endovascular embolisation with Amplatzer vascular plug of ruptured pulmonary artery aneurism in Behçet's disease. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 152-153.	0.8	0
24	Short report: correlates of functional disability with disease activity in elderly patients with rheumatoid arthritis. Psychology, Health and Medicine, 2018, 23, 668-673.	2.4	4
25	Methodology of a new inflammatory arthritis registry: TReasure. Turkish Journal of Medical Sciences, 2018, 48, 856-861.	0.9	7
26	Cavitary pulmonary nodules in rheumatoid arthritis; case reports and review of the literature. European Journal of Rheumatology, 2018, 5, 65-68.	0.6	9
27	Microscopic colitis in patients with Takayasu's arteritis: a potential association between the two disease entities. Clinical Rheumatology, 2016, 35, 2495-2499.	2.2	7
28	Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. Turkish Journal of Haematology, 2015, 32, 43-50.	0.5	7
29	Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Clinical and Experimental Nephrology, 2013, 17, 345-351.	1.6	47
30	Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatology International, 2012, 32, 3277-3279.	3.0	68
31	Improvement of Coronary Flow Velocity Reserve with Telmisartan in Patients with Autosomal-Dominant Polycystic Kidney Disease. Southern Medical Journal, 2010, 103, 409-413.	0.7	5
32	Assessment of Adrenal Functions in Patients with Autosomal Dominant Polycystic Kidney Disease. Experimental and Clinical Endocrinology and Diabetes, 2010, 118, 741-746.	1.2	3
33	Amyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 226-231.	3.0	17
34	Thrombotic thrombocytopenic purpura associated with multiple myeloma. Blood Coagulation and Fibrinolysis, 2008, 19, 439-441.	1.0	10
35	Leukocytoclastic Vasculitis due to Thalidomide in Multiple Myeloma. Japanese Journal of Clinical Oncology, 2007, 37, 704-707.	1.3	19
36	Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report. Mycoses, 2007, 51, 070726205023005-???.	4.0	2

#	Article	IF	CITATIONS
37	Analysis of Bone Mineral Density, Biochemical Bone Turnover Markers and Serum Tryptase Levels in Patients with Systemic Mastocytosis (SM) Blood, 2007, 110, 4662-4662.	1.4	Ο
38	Granulomatosis with Poliangiitis (GPA). Acta Medica, 0, 52, 35-38.	0.2	0